Approval Year
| Substance Class |
Concept
|
| Record UNII |
7EM2VXC85Q
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
810021
Created by
admin on Sat Dec 16 18:23:34 GMT 2023 , Edited by admin on Sat Dec 16 18:23:34 GMT 2023
|
||
|
FDA ORPHAN DRUG |
784020
Created by
admin on Sat Dec 16 18:23:34 GMT 2023 , Edited by admin on Sat Dec 16 18:23:34 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
7EM2VXC85Q
Created by
admin on Sat Dec 16 18:23:34 GMT 2023 , Edited by admin on Sat Dec 16 18:23:34 GMT 2023
|
PRIMARY |
This is a non-substance concept
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
Upon binding to Claudin18.2-expressing tumor cells, NBL-015 mediates antibody-dependent
cellular toxicity (ADCC) in the presence of NK cells
|
This is a non-substance concept